IMMIX BIOPHARMA INC.

Immix Biopharma Subsidiary Nexcella Completes Initial NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site

10 июл 2023 09:47:00 Источник Nasdaq GlobeNewswire

Immix Biopharma Subsidiary Nexcella Completes Pre-IND Meeting with FDA on NXC-201 US Clinical Trial

26 июн 2023 09:49:00 Источник Nasdaq GlobeNewswire

Immix Biopharma Subsidiary Nexcella Appoints Edward J. Borkowski, former Chief Financial Officer of Mylan N.V, to Board of Directors

22 июн 2023 09:53:00 Источник Nasdaq GlobeNewswire

Immix Biopharma Subsidiary Nexcella Appoints Jeffrey H. Cooper, former Chief Financial Officer of BioMarin, to Board of Directors

20 июн 2023 09:45:00 Источник Nasdaq GlobeNewswire

Immix Biopharma Subsidiary Nexcella Appoints Mary Sue Coleman, former Johnson & Johnson Independent Director, to Board of Directors

16 июн 2023 09:43:00 Источник Nasdaq GlobeNewswire

Immix Biopharma Completes $5 Million At-The-Market Equity Offering Program

14 июн 2023 07:30:00 Источник Nasdaq GlobeNewswire

Immix Biopharma Subsidiary Nexcella Appoints Henry McKinnell, Jr., former Chairman & CEO of Pfizer Inc., to Board of Directors

12 июн 2023 09:49:00 Источник Nasdaq GlobeNewswire

Immix Biopharma Subsidiary Nexcella Announces Commencement of NXC-201 Engineering Batches at its U.S. CAR-T Manufacturing Site

26 май 2023 09:53:00 Источник Nasdaq GlobeNewswire

Immix Biopharma Announces Positive NXC-201 Clinical Results at ASGCT: 100% Overall Response Rate in DARZALEX-Relapsed/Refractory AL Amyloidosis with Zero ICANs in Ongoing NEXICART-1 Phase 1b/2a Clinical Trial

21 май 2023 16:00:00 Источник Nasdaq GlobeNewswire

Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 26th Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT)

04 май 2023 12:30:00 Источник Nasdaq GlobeNewswire

Immix Biopharma Announces Early Positive IMX-110 Interim Clinical Trial Data Demonstrating 100% Tumor Shrinkage in Advanced Metastatic Colorectal Cancer at the Lowest Dose of IMX-110 + BeiGene / Novartis Anti-PD-1 Antibody Tislelizumab

03 май 2023 08:00:00 Источник Nasdaq GlobeNewswire

Nexcella, an Immix Biopharma subsidiary, Announces Positive 58-Patient NXC-201 Clinical Data: 100% Overall Response Rate in Light Chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in Paris

26 апр 2023 17:30:00 Источник Nasdaq GlobeNewswire

Nexcella, an Immix Biopharma subsidiary, announces poster presentation at the European Society for Blood and Marrow Transplantation 49th Annual Meeting

04 апр 2023 08:00:01 Источник Nasdaq GlobeNewswire

Nexcella, an Immix Biopharma Subsidiary, Announces 2023 Haematologica Editorial Highlighting NXC-201 Efficacy In The Context of U.S. Food And Drug Administration Approved BCMA CAR T Cells

31 мар 2023 08:00:00 Источник Nasdaq GlobeNewswire

Nexcella, an Immix Biopharma Subsidiary, Announces New Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in AL Amyloidosis Patients + Additional Positive Multiple Myeloma Safety Data Demonstrating NXC-201 Outpatient CAR-T Treatment Potential

23 мар 2023 08:00:01 Источник Nasdaq GlobeNewswire

Immix Biopharma Confirms No Exposure to Silicon Valley Bank or Silvergate Bank

10 мар 2023 19:45:20 Источник Nasdaq GlobeNewswire

ImmixBio to Discuss Recent Positive NXC-201 Clinical Data in AL Amyloidosis and Multiple Myeloma at the 35th Annual Roth Conference on March 14

06 мар 2023 08:00:00 Источник Nasdaq GlobeNewswire

Nexcella Announces 50 Patients Already Treated with CAR-T NXC-201; Estimates 100-Patient Total Enrollment for U.S. Food and Drug Administration Approval BLA Submission

27 фев 2023 08:45:00 Источник Nasdaq GlobeNewswire

Immix Biopharma Subsidiary Nexcella Enters into U.S. GMP Manufacturing Agreement to Expand Ongoing NXC-201 Phase 1b/2 Clinical Trial to the U.S.

15 фев 2023 08:30:00 Источник Nasdaq GlobeNewswire

Immix Biopharma Subsidiary Nexcella, Inc. Presents 42-Patient Interim Data, with 90% Overall Response Rate in Relapsed or Refractory Multiple Myeloma at NXC-201 Therapeutic Dose from its Phase 1 Expansion Trial at the 5th European CAR T-cell Meeting

09 фев 2023 08:00:01 Источник Nasdaq GlobeNewswire